Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

The causal relationship of liver disease to neuropathy has been questioned. This study was designed to evaluate the incidence and character of peripheral neuropathy in patients with liver cirrhosis.

Some diseases producing liver dysfunction can independently cause peripheral neuropathy. Hence, a cause and effect relationship between liver disease and neuropathy has been questioned.

is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders ... as a potential treatment for acute and chronic neuropathic ...

"We believe QUTENZA® may be a clinically meaningful treatment option that could address the unmet needs of many patients in the United States who suffer from Post-surgical neuropathic pain and may not ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

A team of international researchers including those from the University of Adelaide have taken a well-known chemical reaction ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that ...

(HealthDay News) — Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according to a ...